FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new halogenised pyrazolo[1,5-a]-pyrimidines of general formula (I) and their pharmaceutically acceptable salts possessing affinity with respect to α1-,α2 subunits of a GABAA receptor. In formula 
R represents alkyl(C1-C6); R1 is specified in a group consisting of alkyl(C1-C6) and alkinyl(C1-C6); X represents a halogen atom, and Y is specified in a group consisting of -CO- and -SO2. The invention refers to intermediate enamine compounds and methods for preparing them.
EFFECT: invention also refers to a method for preparing the compounds of formula (I), the based pharmaceutical compounds, to the use of said compounds for preparing said drug preparation for treating or preventing anxiety, epilepsy, sleep disorders, including insomnia, as well as for inducing a sedative-hypnotic effect, anaesthesia and muscular relaxation.
23 cl, 6 tbl, 10 ex
| Title |
Year |
Author |
Number |
| PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION SHOWING ABILITY TO INHIBIT GABA RECEPTORS, AND DRUG FOR TREATING AND PREVENTING DISORDERS ASSOCIATED WITH GABA RECEPTOR INHIBITION |
2007 |
- Anglada Luis
- Gul'Etta Antonio
- Palomer Al'Bert
|
RU2458063C2 |
| N-(5-ACETYL-2-FLUOROPHENYL)-N-METHYLACETAMIDE, METHOD OF PRODUCING N-[5-(3-DIMETHYLAMINO-ACRYLOYL)-2-FLUOROPHENYL]-N-METHYLACETAMIDE AND METHOD OF PRODUCING N-{2-FLUORO-5-[3-THIOPHENE-2-CARBONYL-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL]PHENYL}-N-METHYLACETAMIDE |
2010 |
- Markil'Jas Fransisko
- Sal'Jares Rosel' Khuan
|
RU2503655C2 |
| AMORPHOUS FORM OF N-{2-FLUORINE-5-[3-(THIOPHEN-2-CARBONYL)-PIRAZOLO[1,5-a]-PYRIMIDIN-7-YL]-PHENYL)-N-METHYL-ACETAMIDE, METHOD FOR PREPARING IT, PHARMACEUTICAL COMPOSITION (VERSIONS) CONTAINING SAID AMORPHOUS FORM AND DRUG AND METHOD OF TREATING AND/OR PREVENTING NERVOUS DISORDERS |
2007 |
- Anglada Luis
- Gul'Etta Antonio
- Palomer Al'Bert
|
RU2450005C2 |
| POLYMORPHIC MODIFICATION IN N-{5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL]-2-FLUORO-PHENYL}-N-METHYL-ACETAMIDE (VERSIONS), CONTAINING IT PHARMACEUTICAL COMPOSITION (VERSIONS), MEDICATION, METHOD OF OBTAINING SAID POLYMORPHIC MODIFICATION (VERSIONS) AND METHOD OF TREATMENT AND/OR PREVENTION OF NERVOUS DISORDERS |
2007 |
- Anglada Luis
- Gul'Etta Antonio
- Palomer Al'Bert
|
RU2413729C2 |
| IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS (VERSIONS), METHOD FOR PREPARING IMIDAZO[1,2-b]PYRIDAZINE COMPOUNDS (VERSIONS), PHARMACEUTICAL COMPOSITION AND DRUG PREPARATION FOR TREATING AND/OR PREVENTING DISEASES RELATED TO GAB RECEPTOR INHIBITION |
2007 |
- Gul'Etta Antonio
- Palomer Al'Bert
- Fal'Ko Khose Luis
|
RU2486188C9 |
| METHOD OF PRODUCING N-{5-[3-(THIOPHENE-2-CARBONYL)-PYRAZOLE[1,5-a]PYRIMIDIN-7-YL]-2-FLUORO-PHENYL}-N-METHYL-ACETAMIDE IN POLYMORPHIC MODIFICATION B |
2007 |
- Anglada Luis
- Gul'Etta Antonio
- Palomer Al'Bert
|
RU2404984C1 |
| MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH |
2019 |
- Praefke, Bent
- Klefekorn, Filip
- Zelig, Roland
- Albrekht, Volfgang
- Laufer, Shtefan
|
RU2788000C2 |
| BICYCLIC DIHYDROPYRIMIDINECARBOXAMIDE DERIVATIVES AS RHO-KINASE INHIBITORS |
2017 |
- Accetta, Alessandro
- Rancati, Fabio
- Capelli, Anna Maria
- Clark, David Edward
- Tisselli, Patrizia
- Edwards, Christine
- Bhalay, Gurdip
|
RU2778478C2 |
| MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS THROMBIN INHIBITORS |
2011 |
- Short Kevin Majkl
- Fam Son Minkh
- Uillyams Devid Charlz
- Datta Somalee
|
RU2639876C2 |
| 2,6-SUBSTUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
2005 |
- Lim Sungtaek
- Kharris Kejt Dzhon
- Stefani Dehvid
- Gardner Charl'Z Dzh.
- Tsao Bin
- Boffi Rehj
- Gillespi Timoti A.
- Agiar Zhuasi K.
- Khant Khejzel Dzh.
- Desho Ehl'Za A.
|
RU2417990C2 |
